Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.

BMC cancer - 16 Dec 2022

Eriksen Martina, Pfeiffer Per, Rohrberg Kristoffer Staal, Yde Christina Westmose, Petersen Lone Nørgård, Poulsen Laurids Østergaard, Qvortrup Camilla

Abstract excerpt

BACKGROUND: Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median progression free survival (PFS) of 4.3 months. However, a regimen with cetuximab given every second week may have comparable efficacy and is more convenient for patients. While...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Colorectal Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36527039
DOI: 10.1186/s12885-022-10420-x
PMCID: PMC9758813

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.PMID 36527039Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.Semantic proximity Read ↗

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.Semantic proximity Read ↗

Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Real-World Outcomes of First-line and Second-line Chemotherapy with Dabrafeniband Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single CenterSemantic proximity Read ↗

Current perspectives on the treatment of BRAF mutated colorectal carcinoma.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Safety and Efficacy of Triple Therapy Containing Encorafenib, Cetuximab, and Binimetinib for BRAF V600E-Mutated Colorectal Cancer: a Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.Semantic proximity Read ↗

[New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].Semantic proximity Read ↗

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.